EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, NOVEMBER 5, 2020
Media advisory: The full study is linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2020.5745?guestAccessKey=4ac8ddf1-0b6c-428f-b26a-8c77ef56e676&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=110520
What The Study Did: The implementation of swab screening program for COVID-19 cancer patients prior to each cycle of anticancer therapy at a hospital in the United Arab Emirates was assessed in this study.
Authors: Humaid O. Al-Shamsi, M.D., of the Burjeel Oncology-Burjeel Medical City in Abu Dhabi, United Arab Emirates, is the corresponding author.
Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.